

Supplementary Table 1. Procedural characteristics	
Characteristic	n (%) or mean ± SD
Hemodynamic before procedure	
CI, L/min/m²	2.88 ± 0.70
SVC, mmHg	8.43 ± 3.15
IVC, mmHg	8.53 ± 3.44
mPAP, mmHg	25.86 ± 8.13
PAWP, mmHg	12.29 ± 5.02
Access site, n (%)	
Femoral access	60 (100)
Device size used, n (%)	
8F	56 (93.3)
10F	4 (6.7)
Thrombectomy time, min	73.05 ± 30.84
Fluoroscopy duration, minutes	24.1 ± 13.4
Estimated blood loss, mL	100 (30,160)
Mechanical thrombectomy, n (%)	
Thrombus aspiration	57 (95)
Mechanical fragmentation	0
Thrombus aspiration and fragmentation	3 (5)
Patients receiving adjunctive therapy, n (%)	
Catheter-directed thrombolysis	2 (3.3)
Vena cava filter implantation	16 (26.7)
Length of ICU stay, days	2 (2,3,25)
Length of hospital stay, days	9.42 ± 3.94
CI, cardiac index; SVC, superior vena cava; IVC, inferior vena cava; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; ICU, intensive care unit; SD, standard deviation; min, minute.	

Supplementary Table 2. Changes in hemodynamics and vitals following percutaneous mechanical thrombectomy				
	Pre-PMT (mean ± SD)	Post-PMT (mean ± SD)	Change mean (%)	<i>P</i> value
Heart rate, bpm	85.48 ± 16.20	81.08 ± 9.51	-4.40 (5.1)	0.007
SBP, mmHg	128.12 ± 26.38	117.07 ± 12.46	-11.05 (8.6)	0.002
DBP, mmHg	72.44 ± 11.42	69.08 ± 9.07	-3.36 (4.6)	0.053
Respiratory rate, pm	20.45 ± 3.52	19.45 ± 1.75	-1 (4.9)	0.055
SpaO ₂ ,%	95.58 ± 3.03	96.75 ± 3.13	1.17 (1.2)	0.032
Shock index ^a , bpm/mmHg	0.70 ± 0.20	0.70 ± 0.10	0	0.996
sPAP, mmHg	40.95 ± 14.68	36.05 ± 10.77	-4.90 (12.0)	< 0.001
dPAP, mmHg	17.03 ± 5.68	14.67 ± 4.59	-2.44 (13.9)	< 0.001
mPAP, mmHg	25.48 ± 8.26	22.08 ± 6.06	-3.40 (13.3)	< 0.001
mPAP (baseline ≥ 20 mmHg)	33.50 ± 9.2	25.10 ± 5.59	-8.40 (25.1)	< 0.001
mMRC score	2.52 ± 1.24	1.22 ± 1.03	-1.30 (51.6)	< 0.001
hs Tnl, ng/mL	0.018 (0.01, 0.08)	0.017 (0.01, 0.05)	-0.001 (5.6)	0.192
NT-proBNP, pg/mL	2102.3 (556.5, 3772.0)	898.6 (561.1, 1670.6)	-1203.7 (57.3)	< 0.001
BUN, mmol/L	6.86 ± 3.37	7.34 ± 5.21	0.48 (7.0)	0.540
Creatinine, μmol/L	80.18 ± 26.39	90.87 ± 76.67	8.54 (13.3)	0.359
Hemoglobin, g/L	109.40 ± 38.56	108.74 ± 16.17	-0.66 (0.6)	0.693
Platelet, 10 ⁹ /L	180.95 ± 64.69	195.61 ± 87.16	14.66 (8.1)	0.064
All hemodynamic and vital values were assessed immediately after the procedure. Dyspnoea score and laboratory tests were evaluated 48 hours postoperatively. a, Shock index defined as the ratio of heart rate to SBP. SBP, systolic blood pressure; DBP, diastolic blood pressure; SpaO ₂ , peripheral arterial oxygen saturation; sPAP, systolic pulmonary artery pressure; dPAP, diastolic pulmonary artery pressure; mPAP, mean pulmonary artery pressure; mMRC, modified Medical Research Council; hs Tnl, high sensitive cardiac troponin I; NT-proBNP, N-Terminal pro-brain natriuretic peptide; BUN, blood urea nitrogen; SD, standard deviation.				

Supplementary Table 3. Baseline demographics and clinical characteristics of the anticoagulant- treated patients	
Characteristic	Baseline
Age, years	79.00 ± 3.86
Female	28 (46.7)
BMI, kg/m²	23.84 ± 3.30
Symptoms duration, days	7.34 ± 5.18
Co-morbidities	
Coronary artery disease	8 (13.3)
Diabetes mellitus	6 (10.0)
Chronic pulmonary disease	11 (18.3)
Prior PE	2 (3.3)
Chronic kidney disease	2 (3.3)
COVID-19	3 (5)
Active cancer	7 (11.7)
Cerebrovascular accident	6 (10.0)
Recent surgery	5 (8.3)
Concomitant DVT	28 (46.7)
Vital signs	
Heart rate, bpm	77.23 ± 8.72
SBP, mmHg	126.39 ± 20.02
DBP, mmHg	71.66 ± 10.59
Respiratory rate, pm	19.18 ± 3.31
mMRC score	2.47 ± 1.16
sPESI ≥ 1	60 (100)
PE severity	
Intermediate-low	46 (76.7)
Intermediate-high risk	14 (23.3)
High risk	0 (0)
Positive biomarkers	39 (65)
PE location	
Saddle	0 (0)
Unilateral	11 (18.3)
Bilateral	49 (81.7)
Clot burden scores	22.10 ± 15.17
Complicated with pulmonary infarction	7 (11.7)
Outcomes at 3 months	
PE-related mortality	0
All-cause mortality	3
Clinical deterioration	0
PE recurrence	1
Bleeding event	1
BMI, body mass index; PE, pulmonary embolism; COVID-19, coronavirus disease 2019; DVT, deep vein thrombosis; sPESI, simplified Pulmonary Embolism Severity Index.	

Supplementary Table 4. Baseline characteristics in patients with high and low clot burden			
Characteristic	Low clot burden (n = 30)	High clot burden (n = 30)	<i>P</i> value
Age, years	80.21 ± 4.65	78.76 ± 3.24	0.174
Female, n (%)	12 (40)	16 (53.3)	0.301
BMI, kg/m²	22.34 ± 3.99	23.51 ± 3.89	0.255
Heart rate, bpm	83.13 ± 15.22	89.33 ± 14.27	0.109
sPESI ≥ 1	20 (66.7)	21 (70)	0.781
High risk, n (%)	4 (13.3)	11 (36.7)	0.037
PE location, n (%)			
Saddle	0	3 (10)	< 0.001
Unilateral	8 (26.7)	1 (3.3)	
Bilateral	22 (73.3)	26 (86.7)	
NT-proBNP, pg/mL	1078.9 (411.4, 3355.6)	2493.7 (828.5, 4052.6)	0.098
RV/LV ratio	1.10 ± 0.18	1.20 ± 0.17	0.139
mPAP, mmHg^a	20.80 ± 6.10	30.17 ± 7.50	< 0.001
mMRC score^b	2.21 ± 1.20	2.89 ± 1.10	0.031
Complicated with pulmonary infarction, n (%)	13 (43.3%)	4 (13.3%)	0.01
Device size used, n (%)			
6F	9 (30)	10 (33.3)	< 0.001
8F	21 (70)	16 (53.3)	
16F	0	4 (13.3)	
Thrombectomy time, min	113.67 ± 46.61	151.55 ± 38.48	0.001
Estimated blood loss, mL	30 (20,90)	160 (125,200)	< 0.001
Length of ICU stay, days	2 (1.5,4)	2 (2,3)	0.801
Length of hospital stay, days	10.97 ± 5.10	8.5 ± 3.7	0.036

a, a total of 58 patients had mPAP measurement including 30 patients with low clot burden and 28 patients with high clot burden. b, there were 2 patients in each group who did not receive dyspnea score due to invasive ventilator treatment. NT-proBNP, N-Terminal pro-brain natriuretic peptide; PE, pulmonary embolism; RV/LV ratio, right ventricular-to-left ventricular ratio; mPAP, Mean pulmonary artery pressure; mMRC, modified Medical Research Council; ICU,intensive care unit; BMI, body mass index; sPESI, simplified Pulmonary Embolism Severity Index; min, minute.